The purpose of this study is to see how well LY3938577 works and how safe it is compared to degludec in people with type 2 diabetes. Participation in the study will last about 26 weeks.
Have type 2 diabetes
Are receiving ≥20 units of basal insulin per day and ≤55 units/day and ≤1.5 units/kg/day at screening
Have hemoglobin A1c (HbA1c) 7.5% to 10.5% inclusive
Have a body mass index (BMI) of 20 or higher and less than 35 kilograms per square meter (kg/m2)
Have type 1 diabetes
Eli Lilly and Company
Lead sponsor